Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Personalis (PSNL)
:PSNL
Holding PSNL?
Track your performance easily
PSNL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $7.20
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.22M
Market Cap
$339.48M
Enterprise Value$229.96M
Total Cash (Recent Filing)$22.62M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Feb 20, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding71,019,875
10 Day Avg. Volume915,513
30 Day Avg. Volume1,216,021
Standard Deviation0.34
R-Squared0.08
Alpha0.00683
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.86
Price to Cash Flow (P/CF)-13.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit12.63
Enterprise Value/Ebitda-2.79
Forecast
1Y Price Target
$8.05Price Target Upside68.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Personalis News
Bulls Say, Bears Say
Bulls Say
Contract ExtensionThe multi-year contract extension with Moderna to use the ImmunoID NeXT platform for the clinical development of its personalized mRNA vaccine, V940, supports long-term revenue growth for Personalis.
Revenue And Earnings BeatPersonalis reported preliminary 4Q24 revenues of approximately $16.8M, exceeding both analyst estimates and consensus, highlighting strong financial performance and market demand.
Strategic InvestmentMerck's $50M equity investment not only extends Personalis' cash runway but also underscores the growth potential of the company's NeXT Personal ultrasensitive minimal residual disease (MRD) testing business and the ImmunoID NeXT platform.
Bears Say
Agreement And Trial CompletionTermination of NTRA agreement and completion of MRNA/MRK phase 3 trial enrollment limit near-term upside.
Revenue DeclineA 21% YoY decline in the VA MVP revenues was noted, partially offsetting the higher biopharma revenues.
Sales PerformanceThe sales decline was due to the decline in revenue from Natera and the V A MVP, both of which were expected.
---
Ownership Overview
25.51% Insiders
5.16% Mutual Funds
0.07% Other Institutional Investors
56.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $1.12 and its highest was $7.20 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $339.48M.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on Nov 06, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.29.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.28.
How many shares outstanding does Personalis have?
Personalis has 71,019,875 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -22.581%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
---
Personalis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.05 (68.41% Upside)
$8.05 (68.41% Upside)
Hedge Fund Trend
Increased
By 744.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.42%
12-Months-Change
Fundamentals
Return on Equity
-57.52%
Trailing 12-Months
Asset Growth
5.85%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
---
PSNL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates strong revenue growth and successful capital raising, which are positive signs for Personalis' future. However, the net loss increase and expected revenue decline in the next quarter present challenges. Overall, the positive aspects slightly outweigh the negatives, as the company seems well-positioned for future growth, particularly in the MRD market.Read More>---
PSNL Stock 12 Month Forecast
Average Price Target
$8.05
▲(68.41% Upside)
Technical Analysis
QuidelOrtho
―
Guardant Health
―
10x Genomics
―
Fulgent Genetics
―
Exact Sciences
―
West Pharmaceutical Services
―
Best Analysts Covering PSNL
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+101.55%
reiterated a buy rating 12 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +101.55% per trade.
---